METHODS:This study was a clinical prospective observational study. It enrolled in 269 eyes of 269 patients who were diagnosed retinopathy, and all patients receive conbercept intravitreal injection. Among them, 143 were males and 126 were females. There were 201 cases of age-related macular degeneration(ARMD)and 68 cases of other retinopathy patients. The mean age was 62.86±11.74 years. Non-contact pneumatic tonometer was used to measure the IOP of the patients before, 10, 30min, 2 and 4h after injection. The group was divided according to the IOP elevation 10min after injection. The IOP elevation 10 mmHg and above was defined as the IOP elevation group, and the IOP elevation less than 10 mmHg was defined as the IOP stable group. Multivariate Logistic regression analysis was used to analyze the differences between the two groups.

RESULTS:The average IOP of patients at 10, 30min, 2 and 4h after injection was 24.1, 20.2, 19.5 and 16.9 mmHg, respectively. The average IOP at each time point after injection was 6.7, 3.1, 1.7 and 0.5 mmHg higher than that before injection. Among them, 56 cases of increased IOP, 213 cases of stable IOP. There were no significant differences in age, best corrected visual acuity(BCVA), gender, eye side and disease type between two groups(all P>0.05). There were statistically significant differences in the number of injection(Z=-4.389, P=0.012), IOP before injection and IOP at each time point after injection(t=-5.343, -10.467, -8.933, -6.124, -4.635, all P<0.01). Multivariate Logistic regression analysis showed that baseline IOP was positively correlated with IOP increase 10min after injection(B=-0.913, OR=0.521, 95%CI: 0.211-0.694, P=0.011).

CONCLUSION: The higher the baseline IOP, the higher risk of elevated IOP after injection. The factor associated with a short-term increase in IOP after intravitreal injection of conbercept was baseline IOP. The number of injection may be another risk factor.